Brief: Kailera Therapeutics Says Phase 2 Ribupatide Oral Shows Up To 12.1% Mean Weight Loss At 26 Weeks
06/06/2026 24:40
BRIEF-Kailera Therapeutics Says Phase 2 Ribupatide Oral Shows Up To 12.1% Mean Weight Loss At 26 Weeks June 5 (Reuters) - Kailera Therapeutics Inc KLRA.O:
KAILERA THERAPEUTICS - PHASE 2 RIBUPATIDE ORAL SHOWS UP TO 12.1% MEAN WEIGHT LOSS AT 26 WEEKS
KAILERA THERAPEUTICS - RIBUPATIDE INJECTION SINGLE DOSE SHOWS UP TO 5.5% MEAN WEIGHT LOSS AT DAY 29
Source text: ID:nGNX2QQG3y
Further company coverage: KLRA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kailera Therapeutics
See all newsChina biotech's ingenuity extends to dealmaking
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
China biotech's ingenuity extends to dealmaking
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Kailera Therapeutics Announces Completion Of Enrollment In Kainetic Global Phase 3 Clinical Program Of Glp-1/Gip Receptor Dual Agonist Ribupatide Injection